Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bio-Rad Laboratories (BIO)

Bio-Rad stockholders approve amended incentive plan, reject dual-class proposal

Neutral Impact 2 of 5 shareholder Written later

At its April 21, 2026 annual meeting, Bio-Rad stockholders approved an amended 2017 Incentive Award Plan that adds 335,000 shares and extends the plan's expiration to March 18, 2036. Stockholders also elected the six nominated directors, ratified KPMG LLP as auditor for fiscal 2026, and approved executive compensation on an advisory basis. A stockholder proposal on the dual class capital structure was not approved.

Key points

  • Amended 2017 Incentive Award Plan approved, adding 335,000 shares and extending expiration to March 18, 2036
  • Dual class capital structure proposal received 1,469,297 votes for and 5,459,554 votes against, and was not approved
  • KPMG LLP ratified as independent auditor for the fiscal year ending December 31, 2026, with 7,037,199 votes for and 38,994 against

The filing

CompanyBio-Rad Laboratories (BIO)
Form8-K, current report
Filed with the SECApr 24, 2026, 4:30 PM ET
Accession number0000012208-26-000024

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 24, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.